Generic Betahistine ( Betahistine )

Buy Generic Betahistine (Betahistine) without prescription in Canada

Betahistine (8 mg, 16 mg, 24 mg): Comprehensive Patient Information for Canada

Basic Product Information

Mechanism of Action

In simple terms: Betahistine is a medicine that helps improve blood flow in the inner ear and reduces the pressure that builds up there. It works by mimicking the effects of histamine, a natural substance in your body. By improving circulation and reducing pressure, it helps relieve dizziness (vertigo), ringing in the ears (tinnitus), and hearing loss associated with Ménière's disease. It is generally well tolerated and should be taken with food.

For specialists: Betahistine is a structural analog of histamine that acts as a weak partial postsynaptic histamine H1 receptor agonist and a presynaptic H3 receptor antagonist. The mechanism of action of the drug appears to depend mainly on its action on H3 receptors mediated by two metabolites, aminoethylpyridine and hydroxyethylpyridine. Animal and human studies indicate betahistine blocks the presynaptic histamine H3 receptors on the histaminergic nerve terminals originating from the tuberomammillary nuclei of the posterior hypothalamus. This blockade upregulates histamine turnover and release, which contributes to central neural compensation in the presence of peripheral vestibular imbalance. Betahistine also produces post-synaptic inhibition of the excitability of primary afferent neurons in the vestibular endorgans, which may help reduce vertigo. The drug improves microcirculation in the inner ear, reduces endolymphatic pressure, and promotes vestibular compensation.

Pharmacokinetics

• Absorption: Betahistine is rapidly and almost completely absorbed from the gastrointestinal tract after oral administration. The plasma concentration of 2-pyridylacetic acid (2-PAA), the major metabolite, reaches its maximum approximately 1 hour after intake.
• Metabolism: Betahistine undergoes almost complete first-pass metabolism. It is rapidly and almost completely metabolized into 2-PAA, which has no pharmacological activity. The plasma concentrations of the parent drug are less than 0.5 ng/mL, suggesting that betahistine undergoes almost complete first-pass metabolism.
• Distribution: The plasma protein binding of betahistine is less than 5%.
• Elimination: The plasma half-life of betahistine is approximately 3.5 hours. More than 85% of the administered dose is excreted in the urine within 24 hours. In a pharmacokinetic study after a single 24 mg dose, the Cmax of 2-PAA was 339.4 ng/mL (range 77.3–776.4 ng/mL), and the t1/2 was 5.2 hours (range 2.0–11.4 hours).
• Onset of Action: Symptomatic improvement in vertigo and dizziness typically begins within the first few weeks of treatment.
• Duration of Action: The therapeutic effect is maintained with continued daily dosing. The half-life of 3.5 hours supports multiple daily dosing to maintain steady plasma concentrations.

Uses in Daily Life and Best Practice Advice

Betahistine is prescribed in Canada for the treatment of vertigo, tinnitus, hearing loss, and nausea associated with Ménière's disease. Your physician will determine the appropriate use and dose based on your specific medical situation.

• Typical Uses: Symptomatic treatment of vertigo, tinnitus, hearing loss, and nausea associated with Ménière's syndrome. It is used to reduce the frequency and severity of vertigo attacks and to improve quality of life in patients with this condition.
• Administration: Take the tablet orally with food, preferably in the middle of meals. The usual adult dosage is 24 to 48 mg per day, divided into three equal doses. Your physician may adjust the dose according to your response.
• Monitoring: If symptoms do not improve or worsen, consult your physician. Regular follow-up is important to assess effectiveness and manage side effects.
• Do Not Stop Without Medical Advice: Do not stop taking this medication without consulting your physician, as your symptoms may return.

Morning vs. Evening Dosing

Betahistine is typically taken three times daily with meals. There is no specific clinical recommendation for morning versus evening dosing. Taking it with meals helps with consistency and reduces the chance of stomach upset. Always follow the schedule recommended by your physician.

• Three Times Daily: The daily dose is usually divided into three equal doses taken with meals.
• Consistency: Take betahistine at the same times each day to ensure consistent effects.
• Missed Dose: If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time.
• Professional Guidance: Your healthcare provider may adjust the frequency and timing based on your response to treatment.

Administration With or Without Food

Betahistine should be taken with food, preferably in the middle of meals. Taking it with food improves absorption and helps reduce the risk of gastrointestinal upset.

• Take the tablet with a meal or snack.
• Swallow the tablet whole with a full glass of water.
• Do not crush or chew the tablet.
• Avoid taking betahistine on an empty stomach.
• If you experience stomach discomfort, taking the tablet with food may help alleviate it.

Interaction Warnings

Indications for Betahistine

"Off-label" means use outside the official approved indication, usually based on current medical guidelines and scientific evidence.

Dosing According to Clinical Indication

Doses should always be adjusted according to the advice of your physician and depending on your health condition. Betahistine should be taken with food. The recommended initial daily dose is 24 mg, divided into three equal doses. The maximum daily dose is 48 mg.

Side Effects and Safety Profile

Guidelines for Correct Use

• Take betahistine exactly as prescribed by your physician. Do not change your dose without medical advice.
• Take the tablet with a meal or snack, preferably in the middle of meals.
• Swallow the tablet whole with a full glass of water. Do not crush or chew.
• Do not exceed the maximum daily dose of 48 mg.
• Do not stop taking this medication without consulting your physician.
• If you are pregnant, planning to become pregnant, or breastfeeding, consult your physician before use.
• If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not double the dose.
• Store at room temperature in a dry place. Keep out of reach of children.

Alternative Treatment Options

• Cinnarizine/Dimenhydrinate Combination: A fixed low-dose combination of cinnarizine 20 mg and dimenhydrinate 40 mg. Commonly used as a therapeutic option for vertigo, with a distinct antivertigo profile compared with betahistine.
• Ginkgo Biloba Extract (EGb 761): A standardized extract that has demonstrated comparable efficacy and good safety in treating dizziness or vertigo of unclear etiology. It is considered a safe and effective alternative to betahistine with comparable efficacy and good tolerability.
• Caroverine plus Ginkgo Biloba: Combination therapy that was the most effective in reducing the handicap of moderate tinnitus in a comparative analysis.
• Prochlorperazine (Stemetil): A phenothiazine antiemetic used for vertigo and nausea. Available in oral, rectal, and injectable forms.
• Dimenhydrinate (Gravol): An antihistamine antiemetic available over the counter for motion sickness and vertigo.
• Flunarizine: A calcium channel blocker used for vertigo and migraine prophylaxis. Available in some jurisdictions but not commonly used in Canada.

Comparison: Betahistine is the most commonly prescribed drug for vertigo in many countries and is specifically indicated for Ménière's syndrome. It is distinguished by its dual mechanism as an H1 agonist and H3 antagonist, which improves inner ear circulation and promotes vestibular compensation. Cinnarizine/dimenhydrinate combination and Ginkgo biloba extract are effective alternatives with different mechanisms of action. Ginkgo biloba extract has shown comparable efficacy and better tolerability in some studies. Your physician will determine the best option for your specific condition.

Legal Status, Registration, and Coverage in Canada

• Registration: Betahistine dihydrochloride is authorized for sale in Canada by Health Canada as a prescription drug. Serc is the reference brand. Generic formulations include Auro-Betahistine (DIN 02449153 for 16 mg, DIN 02449161 for 24 mg), M-Betahistine (DIN 02519682), Mint-Betahistine (DIN 02536765), Teva-Betahistine (DIN 02280183 for 8 mg), PMS-Betahistine, NRA-Betahistine (DIN 02544938 for 16 mg), and Sanis Betahistine (DIN 02525011 for 8 mg). Some products are listed as Dormant or Cancelled Post Market in the Health Canada database.
• Prescription Status: Prescription only in Canada.
• Coverage: Coverage varies by province and territory. In Manitoba, Serc 24 mg is listed as a Part 1 Benefit on the Pharmacare formulary. In Newfoundland and Labrador, Serc 24 mg and M-Betahistine 24 mg are listed as open benefits with no criteria or prior approval. In Ontario, Mint-Betahistine 16 mg is listed as an Off-Formulary Interchangeable product and Exceptional Access Program product at a drug benefit price of $0.3557 per tablet. In Quebec, betahistine is covered under the RAMQ formulary, but stock ruptures have been reported for several products including NRA-Betahistine, PMS-Betahistine, Teva-Betahistine, and M-Betahistine. Generic formulations are generally more affordable than brand-name products.
• Pharmacovigilance: Adverse reactions should be reported to Health Canada's MedEffect Canada program.

Recent Research and Clinical Guidelines (2022–2026)

• A 2025 systematic literature review compared the efficacy and safety of the cinnarizine/dimenhydrinate combination versus betahistine in the treatment of vertigo. Betahistine and the fixed low-dose combination of cinnarizine 20 mg and dimenhydrinate 40 mg are commonly used therapeutic options, each with distinct antivertigo profiles.
• A 2026 randomized double-blind controlled trial found that EGb 761 (Ginkgo biloba extract) and betahistine demonstrated comparable efficacy and good safety in treating dizziness or vertigo of unclear etiology. EGb 761 is a safe and effective alternative to betahistine with comparable efficacy and good tolerability.
• A 2026 prospective comparative study found that standardized Ginkgo biloba extract (Ginbex) and betahistine demonstrated comparable efficacy in chronic vertigo, with Ginbex showing better tolerability and higher patient satisfaction.
• A 2025 comparative analysis of betahistine alone, caroverine alone, and caroverine plus Ginkgo biloba in moderate tinnitus found that caroverine and Ginkgo biloba combination therapy was the most effective in reducing the handicap of moderate tinnitus.
• Research continues to explore the role of betahistine in various vestibular disorders, including its use in benign paroxysmal positional vertigo (BPPV) compared with lumbrokinase DLBS1033.
• Current clinical practice in Canada continues to recommend betahistine for the symptomatic treatment of Ménière's syndrome, with dosing individualized according to patient response. The recommended initial daily dose is 24 mg, and the maximum daily dose is 48 mg.

Availability and Supply in Canada

Prices and availability may vary by province, territory, and pharmacy. Generic betahistine formulations are widely available in Canada and are generally more affordable than brand-name products. Some products have experienced stock ruptures in Quebec. Check with your local pharmacy for current pricing and availability.

Frequently Asked Questions (FAQ)

1. What is betahistine used for?
   Betahistine is used to treat vertigo, tinnitus (ringing in the ears), hearing loss, and nausea associated with Ménière's syndrome. It helps improve circulation in the inner ear, reducing dizziness and related symptoms.
2. How does betahistine work?
   Betahistine is a structural analog of histamine. It works as a weak H1 receptor agonist and a strong H3 receptor antagonist. This action improves microcirculation in the inner ear, reduces endolymphatic pressure, and promotes central vestibular compensation.
3. What is the correct dose of betahistine?
   The usual initial dose is 16 mg three times daily (48 mg/day). The maintenance dose is generally 24 to 48 mg daily, divided into two or three doses. The maximum daily dose is 48 mg. Your physician will adjust the dose according to your response.
4. Can I take betahistine with food?
   Yes. Betahistine should be taken with food, preferably in the middle of meals. Taking it with food improves absorption and helps reduce the risk of stomach upset.
5. What should I do if I miss a dose?
   If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time.
6. Can I drink alcohol while taking betahistine?
   Avoid excessive alcohol consumption while taking betahistine. Alcohol may worsen vertigo and balance symptoms. A case report describes an interaction between betahistine and ethanol.
7. What are the serious side effects of betahistine?
   Serious side effects include severe skin reactions, difficulty breathing, convulsions, hallucinations, confusion, allergic reactions, low blood pressure, and slow heart-beat. Seek immediate medical attention if you experience these symptoms.
8. Is betahistine safe during pregnancy?
   Betahistine should be used during pregnancy only if clearly needed. There are no adequate data on the use of betahistine in pregnant women. Consult your physician if you are pregnant or planning to become pregnant.
9. Is betahistine safe during breastfeeding?
   It is not known whether betahistine is excreted in human breast milk. Consult your physician before use if breastfeeding.
10. Are there alternatives to betahistine?
    Yes. Alternatives include cinnarizine/dimenhydrinate combination, Ginkgo biloba extract (EGb 761), caroverine plus Ginkgo biloba, prochlorperazine, dimenhydrinate, and flunarizine. Ginkgo biloba extract has shown comparable efficacy and better tolerability in some studies. Your physician will determine the best option for your specific condition.
11. Is betahistine covered by Canadian health insurance?
    Coverage varies by province and territory. In Manitoba, Serc 24 mg is listed as a Part 1 Benefit. In Newfoundland and Labrador, Serc 24 mg and M-Betahistine 24 mg are listed as open benefits. In Ontario, Mint-Betahistine 16 mg is listed as an Off-Formulary Interchangeable product and Exceptional Access Program product. In Quebec, betahistine is covered under the RAMQ formulary. Check with your provincial drug plan and private insurance provider for coverage details.